Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

Cerebrovascular Disease Clinical Trial

Official title: Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

Status Completed

Clinical Trial Summary

This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of mobility and cognitive function linked to white-matter disease (also known as white-matter hyperintensity or WMH) in patients with normal or mildly impaired mobility and cognition in subjects with detectable cerebrovascular disease (>0.5% WMH fraction of intracranial contents). The study patients will be enrolled and randomized to one of two levels of ambulatory blood pressure control (intensive to achieve a goal 24-hour systolic blood pressure of < 130 mmHg or standard to achieve a goal 24-hour systolic blood pressure of < 145 mmHg) for a total of 36 months.

Clinical Trial Description

The study patients will be enrolled and randomized to one of two levels of ambulatory BP control (intensive to achieve a goal 24-hour systolic BP of < 130 mmHg or standard to achieve a goal 24-hour systolic BP of < 145 mmHg) for a total of 36 months. Similar antihypertensive regimens will be used in both of the treatment groups. Titration of antihypertensive therapies will be performed at monthly intervals for the first 3 to 6 months post-randomization to achieve goal systolic BP. The primary and secondary outcomes will be evaluated at baseline, and following 18 months and 36 months of therapy. ;

Related Conditions & MeSH terms

• Cerebrovascular Disease
• Cerebrovascular Disorders
• Hypertension
• Hypertension, Systolic

• NCT number: NCT01650402
• Study type: Interventional
• Source: UConn Health
• Status: Completed
• Phase: N/A
• Start date: December 2011
• Completion date: October 2018